Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 275-284

  Pinto, Ana Catarina ^a,d   Ângelo, Susana ^c,d   Moreira, João Nuno ^a,b   Simões, Sérgio ^a,b,d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d Bluepharma   (Portugal)

Author keywords

Chemosensitization; Dose reduction index; HRPC; Imatinib; Median effect analysis

Indexed keywords

CIPROFLOXACIN; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; IMATINIB; MITOXANTRONE; VINBLASTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; CELL PROLIFERATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; MALE; METASTASIS; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ETOPOSIDE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MITOXANTRONE; NEOPLASM METASTASIS; PIPERAZINES; PROSTATIC NEOPLASMS; PYRIMIDINES; VINBLASTINE;

EID: 79953797151     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1315-z     Document Type: Article

References (48)

1. Goodin S, Rao KV, DiPaola RS (2002) State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 7:360-370 (Pubitemid 34919960)
2. Sonpavde G, Hutson TE, Berry WR (2006) Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 32:90-100 (Pubitemid 43362230)
3. Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S (2003) Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. Tumori 89:349-360 (Pubitemid 37279914)
4. Kamat AM, DeHaven JI, Lamm DL (1999) Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54:56-61 (Pubitemid 29323333)
5. El-Rayes BF, Grignon R, Aslam N, Aranha O, Sarkar FH (2002) Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells. Int J Oncol 21:207-211
6. Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH (2003) Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 22:787-794
7. Hubert A, Lyass O, Pode D, Gabizon A (2000) Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11:123-127 (Pubitemid 30193068)
8. Hande KR (2008) Topoisomerase II inhibitors. Update Cancer Ther 3:13-26 (Pubitemid 351410540)
9. Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514-1521 (Pubitemid 28446331)
10. Kamradt JM, Pienta KJ (2000) Etoposide in prostate cancer. Expert Opin Pharmacother 1:271-275
11. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW (2007) Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97:735-740 (Pubitemid 47396288)
12. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62:115-122 (Pubitemid 40096777)
13. Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400:173-184 (Pubitemid 28475102)
14. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764 (Pubitemid 26185452)
15. Zhou XJ, Rahmani R (1992) Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44 (Suppl 4):1-16 (discussion 66-19) (Pubitemid 23025990)
16. Hardman JG, Limbird LE, Gilman AG (2001) Goodman LSPbot: Goodman & Gilman's the pharmacological basis of therapeutics. In: Hardman JG, Limbird le (eds)/Alfred Goodman Gilman (consulting ed) 10th edn. McGraw-Hill, New York, London
17. Pinto AC, Moreira JN, Simoes S (2009) Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol 64:445-454
18. Chou TC, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4:450-454
19. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
20. Chou TC (1994) Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contrib Gynecol Obstet 19:91-107
21. Budman DR, Calabro A, Kreis W (2002) Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13:1011-1016 (Pubitemid 36020671)
22. Chou TC, Tan QH, Sirotnak FM (1993) Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 31:259-264 (Pubitemid 23029148)
23. Kreis W, Budman DR, Calabro A (2001) A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemother Pharmacol 47:78-82 (Pubitemid 32664517)
24. Wampler GL, Carter WH Jr, Campbell ED, Keefe PA (1992) Relationships between various uses of antineoplastic drug-interaction terms. Cancer Chemother Pharmacol 31:111-117
25. Capranico G, Binaschi M, Borgnetto ME, Zunino F, Palumbo M (1997) A protein-mediated mechanism for the DNA sequencespecific action of topoisomerase II poisons. Trends Pharmacol Sci 18:323-329 (Pubitemid 27404659)
26. Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N (1997) Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry 36:2919-2924 (Pubitemid 27138575)
27. Bakshi RP, Galande S, Muniyappa K (2001) Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol 36:1-37 (Pubitemid 32202689)
28. Montecucco A, Biamonti G (2007) Cellular response to etoposide treatment. Cancer Lett 252:9-18 (Pubitemid 46734551)
29. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH (1999) Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 35:664-671 (Pubitemid 29192979)
30. Barrett JF, Gootz TD, McGuirk PR, Farrell CA, Sokolowski sa (1989) Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother 33:1697-1703 (Pubitemid 19239159)
31. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. J Biol Chem 274:35927-35932 (Pubitemid 129512900)
32. Bromberg KD, Burgin AB, Osheroff N (2003) A two-drug model for etoposide action against human topoisomerase IIalpha. J Biol Chem 278:7406-7412 (Pubitemid 36800745)
33. Liu WM, Joel SP (2003) The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemother Pharmacol 51:291-296 (Pubitemid 36629806)
34. Bromberg KD, Burgin AB, Osheroff N (2003) Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry 42:3393-3398 (Pubitemid 36368632)
35. Boland MP, Fitzgerald KA, O'Neill la (2000) Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem 275:25231-25238
36. Leroy D, Kajava AV, Frei C, Gasser SM (2001) Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 40:1624-1634 (Pubitemid 32144031)
37. Buchdunger E, O'Reilly T, Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38 (Suppl 5):28-36
38. Kubler HR, van Randenborgh H, Treiber U, Wutzler S, Battistel C, Lehmer A, Wagenpfeil S, Hartung R, Paul R (2005) In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 63:385-394 (Pubitemid 40664350)
39. Ostman A, Heldin CH (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97:247-274 (Pubitemid 46528991)
40. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894 (Pubitemid 41252840)
41. van der Poel HG (2004) Smart drugs in prostate cancer. Eur Urol 45:1-17 (Pubitemid 37548987)
42. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741 (Pubitemid 29094544)
43. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44:379-382 (Pubitemid 14177767)
44. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J (1990) Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18:365-380
45. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158-162 (Pubitemid 38114314)
46. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 (Pubitemid 32267972)
47. Naber KG, Sorgel F, Kees F, Jaehde U, Schumacher H (1989) Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Am J Med 87:57S-59S (Pubitemid 20005146)
48. Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, Painter B (1984) Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26:741-744 (Pubitemid 15211673)